Drug Screening

At Sygnature Discovery, our bioscientists collaborate closely with your Chemistry, Computational Chemistry, and DMPK teams. Together, we aim to provide carefully tailored, informative, and efficient drug screening services. We utilise state-of-the-art equipment to ensure that our drug screening services deliver fully characterised hit, lead, and candidate series.

Our scientists can support your project through the provision of reliable, flexible and robust Iterative screening to accelerate your Design-make-test-analyse cycle. In addition, we can undertake tailored Mechanism of Action (MOA) studies to provide a deep understanding of your compounds engagement with the target to inform your compound progression and design strategies.

Our commitment to excellence ensures that you receive the highest quality support for your drug discovery efforts. With our collaborative approach, state-of-the-art equipment, and expertise in Iterative screening and MOA studies, we empower you to make informed decisions and advance your drug development projects with confidence.

Drug Screening Services

Screening Cascade Development

Our experienced scientists design tailored, streamlined, and informative screening cascades to deliver continuous, high-quality, and reliable data throughout your project's lifecycle


Iterative Screening

Design-Make-Test-Analyse cycles to expedite the progression of your project through the discovery pipeline.


Screening Libraries

Accelerate your drug discovery programs with Sygnature Discovery's high-quality Screening libraries and advanced screening technologies. Unleash the power of our compound library combined with Fragment Screening, MTS and HTS, and Virtual Screening to drive transformative research.


Medium and High Throughput Screening

Tailored hit finding solutions for preclinical projects, utilising medium and high throughput screening capabilities at Sygnature Discovery. Benefit from expert scientists, advanced automation platforms, and industry-leading informatics for accurate data and compound tracking.


Fragment Screening

Fragment Based Drug Discovery (FBDD) screens fragment libraries using biophysical techniques, Sygnature Discovery's low complexity collection enhances hit discovery and optimisation, making it effective.


Mechanism of Action (MOA)

Sygnature Discovery is expert at applying different, complementary approaches that can be taken to identify compound Mechanism of Action.


Latest News

View All

Sygnature Discovery and UBE Corporation successfully identify…

Five Arrows invests in Sygnature Discovery

Sygnature Discovery’s Early CMC Development Expansion: Unveiling…

Sygnature Discovery expands US presence with Bay…